This post was originally published on this site Shlomit Norman was 42 when doctors diagnosed her with multiple myeloma — an incurable bone marrow cancer that rarely strikes people under the age of 65. At the time, the youngest of her three boys was 10, and few patients with the disease survived for more than…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Gazyva-Revlimid Effective for Certain Patients with Relapsed or Refractory Follicular Lymphoma, Trial Suggests
This post was originally published on this site A combination of Gazyva (obinutuzumab) and Revlimid (lenalidomide) is effective for some patients with follicular lymphoma who failed prior treatments, including those with early relapses, according to a Phase 2 study in which more than 70% of the patients responded to induction therapy. With a manageable safety…
Study Explains Checkpoint Inhibitors’ Efficacy in PD-L1 Negative Tumors
This post was originally published on this site Immune checkpoint inhibitors targeting the PD-L1 molecule appear to activate immune cells called natural killer (NK) cells, a new study says. This finding may explain why some tumors are responsive to these checkpoint inhibitors even when the PD-L1 checkpoint protein isn’t expressed. The new study, “The mechanism…
Longer Use of Hormone Replacement Therapy Linked to Greater Breast Cancer Risk in Study
This post was originally published on this site The longer women use hormone therapy after menopause the higher is their breast cancer risk over time, and this risk persists for more than a decade after stopping this replacement therapy, a new meta-analysis suggests. “Type and timing of menopausal hormone therapy and breast cancer risk: individual…
Collaborators Work to Develop New Sequencing Methods to Manage Cancers
This post was originally published on this site The nonprofit organization Genome Canada, the pharmaceutical company Thermo Fisher Scientific and the Ontario Institute for Cancer Research (OICR) are collaborating to develop new targeted next generation sequencing (NGS) methods to assess, and possibly improve, the management of pancreatic, prostate, and breast cancer. The three-year, $6 million…
Inherited BRCA2 Mutations Linked to Risk of Non-Hodgkin’s Lymphoma in Children
This post was originally published on this site Inherited mutations in the DNA repair gene BRCA2 — a well-known risk factor for breast and ovarian cancers in adults — also show a significant association with non-Hodgkin’s lymphoma in children and adolescents, a new study found. Survivors of childhood lymphoma, particularly those with a family history of…
Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show
This post was originally published on this site Adding the investigational oral therapy onvansertib to a regimen of Zytiga (abiraterone acetate) and prednisone overcomes resistance to Zytiga in men with metastatic castration-resistant prostate cancer (mCRPC), according to early results of a Phase 2 clinical trial. The study (NCT03414034) is testing whether a once-daily dose of…
‘Don’t Eat Me’ Signal CD24 May Be Promising Therapeutic Target for Ovarian and Breast Cancers, Study Says
This post was originally published on this site Researchers have discovered a “don’t eat me” signal that is deployed by ovarian and breast cancer cells to evade a person’s immune system. Similar to other anti-cancer therapies in use or under testing, blocking this signal raises hope for a new class of immunotherapies to combat these…
FDA Grants Orphan Drug Designation to CARsgen’s CT053 for Multiple Myeloma Treatment
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to CT053, one of CARsgen Therapeutics’ lead CAR T-cell therapies, for the treatment of patients with multiple myeloma. Chimeric antigen receptor T-cell therapy, more commonly known as CAR T-cell therapy, is a type of…
Trial of Targeted Radiation Therapy, CLR 131, in Children with Advanced Cancers Moving to Higher Dose
This post was originally published on this site Cellectar Biosciences announced that a second and higher dose of its investigational radiotherapeutic compound, CLR 131, was cleared for use in its ongoing CLOVER-2 study in children with advanced solid cancers, lymphomas, and brain tumors. The independent committee overseeing the trial recommended moving to a higher dose…
FDA Urges Inclusion of Men in Clinical Trials for Breast Cancer Treatment
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has drafted a series of recommendations urging the inclusion of men in breast cancer clinical trials, aiming to broaden treatment options for these patients. Men are rarely included in clinical trials assessing the effectiveness of medications to treat breast cancer…
LLS Calls on Stakeholders to Combat Soaring Cancer Care Costs
This post was originally published on this site The rising cost of cancer care in the United States is increasingly being passed on to patients, some of whom defer or skip treatments because they can’t afford them, says the Leukemia & Lymphoma Society (LLS), which is seeking more help to address the issue. The society’s…